Disclaimer:All content on this platform is sourced from the internet and is provided for informational purposes only. None of the content represents the views of this site, nor does it constitute investment advice. Please exercise caution when investing.
Eli Lilly is close to finalizing a deal to acquire biotech company Ventyx for $14 per share. (The Wall Street Journal)
Eli Lilly is close to finalizing a deal to acquire biotech company Ventyx for $14 per share. (The Wall Street Journal)
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice. If you find any violations, please Click to Report




